*Department of Pediatrics, School of Medicine, University of California, Davis, CA;
†MIND (Medical Investigation of Neurodevelopmental Disorders) Institute, University of California, Davis, CA;
‡Department of Pediatrics, Naval Medical Center Portsmouth, Portsmouth, VA;
§Divisions of Epidemiology and Environmental and Occupational Health, Department of Public Health Sciences, School of Medicine, University of California, Davis, CA.
Address for reprints: Robin L. Hansen, MD, MIND Institute, Department of Pediatrics, University of California, Davis, 2825 50th Street, Sacramento, CA 95817; e-mail: [email protected].
Supported by the National Institute of Environmental Health Sciences (R01 ES015359, P01 ES11269), the U.S. Environmental Protection Agency through the Science to Achieve Results (STAR) program (R833292 and R829388), and the UC Davis MIND Institute, University of California, Davis.
Disclosure: The authors declare no conflict of interest.
R. S. Akins is a Navy Physician; however, the views expressed in this article are those of the author(s) and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense or the United States Government. K. Angkustsiri participates in clinical trials for fragile X syndrome and autism spectrum disorders funded by Novartis, Roche, Seaside Therapeutics, and Forest Laboratories.
Received June , 2013
Accepted September , 2013
